AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment ...

Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the ...

Air Canada has resumed operations but it will be days before the backlog of flight cancellations are cleared. Many passengers ...

WICHITA, Kan. (KWCH) - On August 18, 2005, 20 years ago, a Sedgwick County judge sentenced Dennis Rader, also known as the ...

Pakistan has seen higher-than-normal monsoon rains since June 26 that have killed at least 645 people across the country, ...

The professor who once taught Bryan Kohberger is still haunted by his crimes and wants answers the court never uncovered.

CLL-314 trial compared the efficacy and safety of pirtobrutinib with ibrutinib in adults with CLL/SLL who were treatment-naïve or who were previously treated and were BTK inhibitor-naïve.

Panelists discuss how providers and payers must collaborate to develop innovative coverage criteria for BTK inhibitors that ...

BAKU, Azerbaijan, August 7. Cooperation in the development of the Baku-Tbilisi-Kars (BTK) railway line was discussed during a meeting between Rovshan Rustamov, chairman of Azerbaijan Railways CJSC ...

NYSE Arca Biotechnology Index | historical charts for BTK to see performance over time with comparisons to other stock exchanges.

Oncology company BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation from the European Medicines Agency (EMA ...